Comparison of Allopurinol And Febuxostat in Asymptomatic Hyperuricemic Patients and their Impact on Serum Creatinine
DOI:
https://doi.org/10.51985/JBUMDC2019070.Keywords:
Allopurinol, Febuxostat, Serum uric acid, Serum creatinine.Abstract
Objective: To determine the effect of Allopurinol & Febuxostat for the treatment of hyperuricemic patients & its influence
on renal function by measuring serum creatinine level.
Study Design & setting: The clinical trial was conducted at Dr. Ruth K M Pfau Civil Hospital, Karachi, during the period
of September 2018 to March 2019
Methodology: 60 patients with sUA > 6.8 mg/dl were registered. A detailed history was taken, patient's baseline serum
Uric Acid (sUA) & serum Creatinine were measured. Patients were divided into two groups to receive Allopurinol, 300
mg & Febuxostat 80 mg, daily for 90-days. The blood parameters were repeated at day 30 and 90.
Results: Group-A (Allopurinol treated patients) baseline uric acid changed from mean 8.79 ± 0.98 mg/dl to 6.40 ± 0.86
mg/dl at day 90. In Group-B (Febuxostat treated patients) sUA baseline mean changed from 8.85 ± 0.97 mg/dl to 5.96 ±
0.68 mg/dl. Mean difference ± SD change of serum uric acid in Group-A was 2.39 ± 1.15 mg/dl and with Group-B it was
2.90 ± 0.87 mg/dl. Mean Serum Creatinine in Group-A changed from 1.54 ± 0.39 mg/dl to mean 1.48 ± 0.40 mg/dl compared
with Group-B where it changed from 1.42 ± 0.30 mg/dl to 1.45 ± 0.31 mg/dl at day-90. Mean difference ± SD of serum
Creatinine in Group-A was 0.11 ± 0.25 mg/dl & in Group-B it was, 0.03 ± 0.15 mg/dl. The above changes were statistically
non-significant with p-value of 0.144.
Conclusion: Allopurinol and Febuxostat treatment resulted in improvement of serum Uric Acid levels while maintaining
their renal function.
References
Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM.
Epidemiology of gout: an update. Best Pract Res Clin
Rheumatol. 2010; 24:811–27
Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic
hyperuricemia: a need for caution. Semin Arthritis Rheum.
; 46:457–64.
Kang DH, Chen W. Uric acid and chronic kidney disease:
new understanding of an old problem. Semin Nephrol. 2011;
(5):447–52.
Jin M & Yang F. Uric acid, hyperuricemia and vascular
diseases, Front Biosci. 2012; 17: 656–669.
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol
in slowing the progression of renal disease through its ability
to lower serum uric acid level. Am J Kidney Dis. 2006;
:51–59
Kang DH, Nakagawa T, Feng L, Watanabe S, et al. A role for
uric acid in the progression of renal disease. J Am Soc Nephrol.
; 13: 2888–2897.
Aung T, Myung G, FitzGerald JD. Treatment approaches and
adherence to urate-lowering therapy for patients with gout.
Patient Prefer Adherence 2017; 11:795–800.
Richette P, Doherty M, Pascual E, Barskova V, et al. 2016
updated EULAR evidence-based recommendations for the
management of gout. Ann Rheum Dis. 2017; 76:29–42.
Becker MA, Kisicki J, Khosravan R. Febuxostat (TMX-67),
a novel, non-purine, selective inhibitor of xanthine oxidase,
is safe and decreases serum urate in healthy volunteers.
Nucleosides Nucleotides Nucleic Acids 2004; 23:1111–16.
Kanwar G and Kabra, R. Serum uric acid level and obesity:
An association. International Journal of healthcare Sciences.
; 4(1):52–55.Kuo CF, Grainge MJ, Zhang W, Doherty M. Global
epidemiology of gout: prevalence, incidence and risk factors.
Nat Rev Rheumatol 2015;11 (11):649–62.
Ling Qiu, Xin-qi, Cheng Jie Wu, Jun-ting Liu. Prevalence of
hyperuricemia and its related risk factors in healthy adults
from Northern and Northeastern Chinese provinces. . 2013;
: 664-72
Stack A, Manolis AJ, Ritz E. Detrimental role of hyperuricemia
on the cardio-Reno vascular system. Curr Med Res Opin.
(Sep); 31 (Suppl 2):21-6.
Becker MA, Schumacher HR Jr, Wortmann RL. Febuxostat
compared with allopurinol in patients with hyperuricemia and
gout, N Engl J Med. 2005; 353: 2450-61.
Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL,
Williams KM. Clinical pharmacokinetics and
pharmacodynamics of allopurinol and oxypurinol. Clin
Pharmacokinet. 2007; 46:623–644
Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana
L. Renal function in gout: long-term treatment effects of
febuxostat. J Clin Rheumatol. 2011;17: 7–13.
Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N,
et al. Effect of treatment of hyperuricemia with allopurinol
on blood pressure, creatinine clearance, and proteinuria in
patients with normal renal functions. Int Urol Nephrol.
;39:1227–33
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites
A, et al. Efficacy of allopurinol and benzbromarone for the
control of hyperuricaemia: a pathogenic approach to the
treatment of primary chronic gout. Ann Rheum Dis 1998; 57:
–9.
Grassi D, Pontremoli R, Bocale R, Ferri C and Desideri G:
Therapeutic approaches to chronic hyperuricemia and gout.
High Blood Press Cardiovasc Prev. 2014. 21:243–250.
Borghi C, Perez-Ruiz F. Urate lowering therapies in the
treatment of gout: a systematic review and meta-analysis.
Mar; 20 (5):983-92.
Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects
of Febuxostat versus allopurinol and placebo in reducing
serum urate in subjects with hyperuricemia and gout: a 28-
week, phase III, randomized, double-blind, parallel-group
trial. Arthritis Rheum. 2008; 59: 1540-8.
Michael A, Becker H, Ralph Schumacher Jr, Robert L,
Wortmann, Patricia A. Febuxostat Compared with Allopurinol
in Patients with Hyperuricemia and Gout. Engl J Med 2005;
:2450-61
Kamatani N, Fujimori N, Hada T. An Allopurinol-Controlled,
Randomized, Double-Dummy, Double-Blind, Parallel
Between-Group, Comparative Study of Febuxostat (TMX-
, a Non-Purine-Selective Inhibitor of Xanthine Oxidase,
in Patients with Hyperuricemia Including Those with Gout
in Japan: Phase 3 Clinical Study Journal of Clinical
Rheumatology. 2011;17(4): S13-S18.
Becker MA, Schumacher HR, Espinoza LR, Wells AF,
MacDonald P, Lloyd E, et al. The urate-lowering efficacy and
safety of Febuxostat in the treatment of the hyperuricemia of
gout: The CONFIRMS trial. 2010; 12 (2):R63
Frampton, JE. Febuxostat: a review of its use in the treatment
of hyperuricemia in patients with gout. Drugs. 2015; 75
(4):427-38.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
